Equities Analysts Set Expectations for Biogen Q2 Earnings

Biogen Inc. (NASDAQ:BIIB) – Research analysts at Zacks Research cut their Q2 2025 EPS estimates for shares of Biogen in a note issued to investors on Thursday, May 15th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will earn $4.09 per share for the quarter, down from their previous forecast of $4.19. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Zacks Research also issued estimates for Biogen’s Q3 2025 earnings at $3.85 EPS, Q4 2025 earnings at $3.67 EPS, FY2025 earnings at $14.64 EPS, Q1 2026 earnings at $3.42 EPS, Q3 2026 earnings at $3.74 EPS and Q4 2026 earnings at $3.68 EPS.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Thursday, May 1st. The biotechnology company reported $3.02 EPS for the quarter, missing the consensus estimate of $3.26 by ($0.24). The firm had revenue of $2.43 billion for the quarter, compared to the consensus estimate of $2.25 billion. Biogen had a net margin of 16.87% and a return on equity of 14.98%. The business’s revenue was up 6.2% on a year-over-year basis. During the same period last year, the company posted $3.67 earnings per share.

A number of other research analysts also recently issued reports on BIIB. Truist Financial reduced their price objective on shares of Biogen from $210.00 to $199.00 and set a “buy” rating on the stock in a research report on Tuesday, April 29th. Mizuho reduced their target price on Biogen from $207.00 to $169.00 and set an “outperform” rating on the stock in a report on Wednesday, May 7th. Royal Bank of Canada lowered their price objective on Biogen from $217.00 to $205.00 and set an “outperform” rating for the company in a research report on Friday, May 2nd. Citigroup reduced their target price on shares of Biogen from $160.00 to $145.00 and set a “neutral” rating on the stock in a research report on Thursday, February 13th. Finally, BMO Capital Markets lowered their price target on shares of Biogen from $156.00 to $139.00 and set a “market perform” rating for the company in a research report on Thursday, February 13th. Twenty research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, Biogen has a consensus rating of “Hold” and an average price target of $191.30.

Biogen Price Performance

Shares of BIIB stock opened at $130.55 on Monday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $238.00. The firm has a market cap of $19.13 billion, a P/E ratio of 11.67, a P/E/G ratio of 1.51 and a beta of 0.12. The business’s 50 day moving average price is $125.55 and its 200-day moving average price is $141.70.

Insider Buying and Selling

In related news, Director Stephen A. Sherwin sold 8,760 shares of the company’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $150.02, for a total value of $1,314,175.20. Following the completion of the transaction, the director now owns 11,318 shares of the company’s stock, valued at approximately $1,697,926.36. This represents a 43.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.16% of the stock is currently owned by insiders.

Institutional Trading of Biogen

Several institutional investors have recently made changes to their positions in BIIB. Vanguard Group Inc. increased its holdings in Biogen by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 17,032,839 shares of the biotechnology company’s stock valued at $2,330,774,000 after acquiring an additional 283,964 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Biogen by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 3,695,476 shares of the biotechnology company’s stock worth $563,709,000 after purchasing an additional 82,456 shares during the last quarter. Pacer Advisors Inc. increased its holdings in shares of Biogen by 13,574.7% in the fourth quarter. Pacer Advisors Inc. now owns 2,667,531 shares of the biotechnology company’s stock worth $407,919,000 after purchasing an additional 2,648,024 shares during the last quarter. Norges Bank bought a new position in Biogen during the fourth quarter valued at approximately $355,569,000. Finally, Invesco Ltd. boosted its stake in Biogen by 6.4% during the first quarter. Invesco Ltd. now owns 2,265,007 shares of the biotechnology company’s stock valued at $309,944,000 after buying an additional 136,200 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.